Poland· PL-100019686
Biostrepta
A streptokinase product containing streptokinasum + streptodornasum, registered in Poland by Wytwórnia Surowic i Szczepionek Biomed Sp. z o.o.. The same ATC class is registered in 3 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Streptokinase is registered in 3 of 19 countries.
Countries holding a registration under ATC B01AD01 (streptokinase), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 3 of them publish a price we can compare per daily dose
Streptokinase · ATC B01AD01
3 / 19 countries
- Finlandprice
- Norwayprice
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Streptokinasum + Streptodornasum
- Manufacturer
- Wytwórnia Surowic i Szczepionek Biomed Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- B01AD01
- ATC class
- Streptokinase
- Defined daily dose
- 1.5 MIO, E
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909990023318
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
130 interactions on record for streptokinase.
Graded by severity as the source publishes them — 46 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Streptokinase · interactions on record
130 records
- 46 severe
- 84 moderate
Most severe, free to view
- WarfarinB01AA03severe
- HeparinB01AB01severe
- DalteparinB01AB04severe
- EnoxaparinB01AB05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Streptokinase in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Bulgaria · Дистрептаза
- Spain · Ernodasa, Varidasa
- Hungary · Distraza
- Malta · Distreptaza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ca86f5a8-edec-44c5-904b-7d84af629689 GET /v1/drugs/ca86f5a8-edec-44c5-904b-7d84af629689?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki ulegające rozpadowi w jamie ustnej",
"source": "urpl",
"strength": "15000 j.m. + 1250 j.m.",
"packaging": "05909990023318 ¦ Rp ¦ 3267\n20 tabl.",
"substance": "Streptokinasum 15000 j.m. + Streptodornasum 1250 j.m.",
"common_name": "Streptokinasum + Streptodornasum",
"pl_product_id": "100019686",
"pozwolenie_nr": "00233",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about streptokinase.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.